Press Releases

Press Releases

    Date Title View
    10/02/22
    Summary ToggleNew Data Reveal Molecular Drivers of Thyroid Eye Disease (TED) May Remain Activated In Patients with Low Clinical Activity Score (CAS)
    PDF Version
    09/29/22
    Summary ToggleHorizon Therapeutics plc Completes Enrollment for Phase 4 Trial of TEPEZZA® (teprotumumab-trbw) in Adults with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)
    PDF Version
    09/22/22
    Summary ToggleHorizon Therapeutics plc Expands Commitment to Education Equity, STEAM Careers and Historically Black Colleges and Universities, Adding Meharry Medical College as Horizon Scholars Partner
    PDF Version
    09/21/22
    Summary ToggleHorizon Therapeutics plc Announces EB Research Partnership Receives 2022 Horizon Prize, Powered by MIT Solve
    PDF Version
    09/19/22
    Summary ToggleHorizon to Highlight Novel Insights in Gout Care During the American College of Rheumatology Convergence 2022
    PDF Version
    09/16/22
    Summary ToggleHorizon Therapeutics plc Makes Founding Gift to Support the University of Notre Dame’s Patient Advocacy Initiative
    PDF Version
    09/14/22
    Summary ToggleData from the MIRROR Randomized Controlled Trial of KRYSTEXXA® (pegloticase) Injection with Methotrexate Published in Arthritis & Rheumatology
    PDF Version
    09/13/22
    Summary ToggleHorizon Therapeutics plc Joins the International Agency for the Prevention of Blindness (IAPB) to Encourage People to #LoveYourEyes this World Sight Day
    PDF Version
    09/12/22
    Summary ToggleHorizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint
    PDF Version
    09/09/22
    Summary ToggleHorizon Therapeutics plc Announces $500 Million Share Repurchase Program
    PDF Version
    Displaying 1 - 10 of 686 results